About AthenaVita
AthenaVita was founded on a simple observation: the healthcare system fails women during the menopause transition.
Traditional models are built around late-stage thresholds, population-based risk scores, and symptom-driven evaluation. This approach delays intervention until disease is already established—missing the critical window when prevention matters most.
The perimenopause and early menopause transition is a period of accelerated cardiovascular risk. Lipid patterns shift. Insulin sensitivity changes. Body composition redistributes. And most of it happens before anything triggers a diagnosis.
AthenaVita exists to close that gap.
Our Clinical Philosophy
We operate differently than traditional healthcare:
Risk is assessed before it becomes diagnostic. We don't wait for abnormal labs.
Trajectory is prioritized over static values. Where you're headed matters more than where you are today.
Sex-specific factors are central, not peripheral. Reproductive history and menopause timing drive risk assessment.
Intervention is proactive and structured. Every recommendation is tied to measurable physiologic targets.
The goal is not short-term optimization. The goal is long-term risk redirection.
Evidence-Based, Not Trend-Based
AthenaVita is anchored in guidelines from the American College of Cardiology, American Heart Association, American Diabetes Association, and The Menopause Society.
We emphasize risk, physiology, and outcomes—not optimization language or unproven protocols.
This is not functional medicine. This is not wellness. This is rigorous, cardiology-informed prevention care.
About The Founder
Kate Freeman is a board-certified nurse practitioner specializing in cardiovascular care and electrophysiology, with over a decade of experience managing complex cardiac patients across both inpatient and outpatient settings.
Her clinical work has centered on the diagnosis, monitoring, and longitudinal management of cardiovascular disease.
This depth of experience exposed a consistent limitation in traditional care: risk is typically addressed only after disease is established, rather than when early physiologic changes first begin to emerge.
AthenaVita was developed to close that gap.
AthenaVita is a clinically grounded model focused on early risk identification, advanced lab interpretation, and structured intervention—designed to assess and redirect cardiometabolic trajectory before the onset of disease. Her approach is built in physiology, data, and long-term risk modeling, not symptom-based care or generalized wellness strategies.
Her work is particularly focused on women in midlife, where shifts in metabolic and hormonal physiology accelerate cardiovascular risk—often years before it is detected in standard evaluations.
Kate Freeman practices in Arizona.